A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

@article{Kelly2007APS,
  title={A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.},
  author={C. Kelly and R. Arnold and Y. Galloway and J. O’Hallahan},
  journal={American journal of epidemiology},
  year={2007},
  volume={166 7},
  pages={
          817-23
        }
}
The effectiveness of a new group B strain-specific meningococcal vaccine referred to as "MeNZB," developed by Chiron Vaccines (Siena, Italy) in collaboration with the Norwegian Institute of Public Health, was assessed in a prospective observational study following a nationwide vaccination program in New Zealand. The vaccination program began in July 2004, and the study uses data from January 2001 to June 2006. A generalized estimating equation model was used to estimate vaccine effectiveness… Expand
110 Citations
Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
  • 43
  • PDF
MeNZB vaccine and epidemic control: when do you stop vaccinating?
  • 20
Phase II meningococcal B vesicle vaccine trial in New Zealand infants
  • 29
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.
  • 157
  • PDF
...
1
2
3
4
...